EGF repeats of epidermal growth factor‑like domain 7 promote endothelial cell activation and tumor escape from the immune system

Pinte,Sébastien; Delfortrie,Suzanne; Havet,Chantal; Villain,Gaëlle; Mattot,Virginie; Soncin,Fabrice

doi:10.3892/or.2021.8219

EGF repeats of epidermal growth factor‑like domain 7 promote endothelial cell activation and tumor escape from the immune system

Authors:
- Sébastien Pinte
- Suzanne Delfortrie
- Chantal Havet
- Gaëlle Villain
- Virginie Mattot
- Fabrice Soncin
View Affiliations

Affiliations: Université de Lille, CNRS, Institut Pasteur de Lille, UMR 8161‑M3T‑Mechanisms of Tumorigenesis and Target Therapies, 59000 Lille, France
Published online on: November 5, 2021 https://doi.org/10.3892/or.2021.8219
Article Number: 8

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The tumor blood vessel endothelium forms a barrier that must be crossed by circulating immune cells in order for them to reach and kill cancer cells. Epidermal growth factor‑like domain 7 (Egfl7) represses this immune infiltration by lowering the expression levels of leukocyte adhesion receptors on the surface of endothelial cells. However, the protein domains involved in these properties are not completely understood. Egfl7 is structurally composed of the predicted EMI‑, EGF‑ and C‑terminal domains. The present study aimed to investigate the roles of these different domains in tumor development by designing retroviruses coding for deletion mutants and then infecting 4T1 breast cancer cell populations, which consequently overexpressed the variants. By performing in vitro soft‑agar assays, it was found that Egfl7 and its deletion variants did not affect cell proliferation or anchorage‑independent growth. When 4T1 cells expressing either the wild‑type Egfl7 protein or Egfl7 domain variants were implanted in mice, Egfl7 expression markedly promoted tumor development and deletion of the EGF repeats decreased the tumor growth rate. By contrast, deleting any other domain displayed no significant effect on tumor development. The overexpression of Egfl7 also decreased T cell and natural killer cell infiltration in tumors, as determined by immunofluorescence staining of tumor sections, whereas deletion of the EGF repeats inhibited this effect. Reverse transcription‑quantitative PCR analysis of the mechanisms involved revealed that deleting the EGF repeats partially restored the expression levels of vascular cell adhesion molecule 1 and E‑selectin, which were suppressed by overexpression of Egfl7 in endothelial cells in vitro. This resulted in a higher number of lymphocytes bound to HUVEC expressing Egfl7‑ΔEGF compared with HUVEC expressing wild‑type Egfl7, as assessed by fluorescent‑THP‑1 adhesion assays onto endothelial cells. Overall, the present study demonstrated that the EGF repeats may participate in the protumoral and anti‑inflammatory effects of Egfl7.

View Figures

View References

1	Castermans K and Griffioen AW: Tumor blood vessels, a difficult hurdle for infiltrating leukocytes. Biochim Biophys Acta. 1776:160–174. 2007.PubMed/NCBI
2	Wettschureck N, Strilic B and Offermanns S: Passing the vascular barrier: Endothelial signaling processes controlling extravasation. Physiol Rev. 99:1467–1525. 2019. View Article : Google Scholar : PubMed/NCBI
3	Herberman RB, Nunn ME, Holden HT and Lavrin DH: Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells. Int J Cancer. 16:230–139. 1975. View Article : Google Scholar : PubMed/NCBI
4	Shrikant P and Mescher MF: Control of syngeneic tumor growth by activation of CD8⁺ T cells: Efficacy is limited by migration away from the site and induction of nonresponsiveness. J Immunol. 162:2858–2866. 1999.PubMed/NCBI
5	Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, Smyth MJ and Schreiber RD: Adaptive immunity maintains occult cancer in an equilibrium state. Nature. 450:903–907. 2007. View Article : Google Scholar : PubMed/NCBI
6	Wu NZ, Klitzman B, Dodge R and Dewhirst MW: Diminished leukocyte-endothelium interaction in tumor microvessels. Cancer Res. 52:4265–4268. 1992.PubMed/NCBI
7	Kuzu I, Bicknell R, Fletcher CD and Gatter KC: Expression of adhesion molecules on the endothelium of normal tissue vessels and vascular tumors. Lab Invest. 69:322–328. 1993.PubMed/NCBI
8	Piali L, Fichtel A, Terpe HJ, Imhof BA and Gisler RH: Endothelial vascular cell adhesion molecule 1 expression is suppressed by melanoma and carcinoma. J Exp Med. 181:811–816. 1995. View Article : Google Scholar : PubMed/NCBI
9	Griffioen AW, Damen CA, Martinotti S, Blijham GH and Groenewegen G: Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancies: The role of angiogenic factors. Cancer Res. 56:1111–1117. 1996.PubMed/NCBI
10	Dirkx AE, Oude Egbrink MG, Kuijpers MJ, van der Niet ST, Heijnen VV, Bouma-ter Steege JC, Wagstaff J and Griffioen AW: Tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression. Cancer Res. 63:2322–2329. 2003.PubMed/NCBI
11	Soncin F, Mattot V, Lionneton F, Spruyt N, Lepretre F, Begue A and Stehelin D: VE-statin, an endothelial repressor of smooth muscle cell migration. EMBO J. 22:5700–5711. 2003. View Article : Google Scholar : PubMed/NCBI
12	Parker LH, Schmidt M, Jin SW, Gray AM, Beis D, Pham T, Frantz G, Palmieri S, Hillan K, Stainier DY, et al: The endothelial-cell-derived secreted factor Egfl7 regulates vascular tube formation. Nature. 428:754–758. 2004. View Article : Google Scholar : PubMed/NCBI
13	Fitch MJ, Campagnolo L, Kuhnert F and Stuhlmann H: Egfl7, a novel epidermal growth factor-domain gene expressed in endothelial cells. Dev Dyn. 230:316–324. 2004. View Article : Google Scholar : PubMed/NCBI
14	Pinte S, Caetano B, Le Bras A, Havet C, Villain G, Dernayka R, Duez C, Mattot V and Soncin F: Endothelial cell activation is regulated by epidermal growth factor-like domain 7 (Egfl7) during inflammation. J Biol Chem. 291:24017–24028. 2016. View Article : Google Scholar : PubMed/NCBI
15	Díaz R, Silva J, García JM, Lorenzo Y, García V, Peña C, Rodríguez R, Muñoz C, García F, Bonilla F and Domínguez G: Deregulated expression of miR-106a predicts survival in human colon cancer patients. Genes Chromosomes Cancer. 47:794–802. 2008. View Article : Google Scholar : PubMed/NCBI
16	Wu F, Yang LY, Li YF, Ou DP, Chen DP and Fan C: Novel role for epidermal growth factor-like domain 7 in metastasis of human hepatocellular carcinoma. Hepatology. 50:1839–1850. 2009. View Article : Google Scholar : PubMed/NCBI
17	Huang CH, Li XJ, Zhou YZ, Luo Y, Li C and Yuan XR: Expression and clinical significance of EGFL7 in malignant glioma. J Cancer Res Clin Oncol. 136:1737–1743. 2010. View Article : Google Scholar : PubMed/NCBI
18	Zhou L, Li J, Zhao YP, Guo JC, Cui QC, Zhou WX, Zhang TP, Wu WM, You L and Shu H: Prognostic significance of epidermal growth factor-like domain 7 in pancreatic cancer. Hepatobiliary Pancreat Dis Int. 13:523–528. 2014. View Article : Google Scholar : PubMed/NCBI
19	Delfortrie S, Pinte S, Mattot V, Samson C, Villain G, Caetano B, Lauridant-Philippin G, Baranzelli MC, Bonneterre J, Trottein F, et al: Egfl7 promotes tumor escape from immunity by repressing endothelial cell activation. Cancer Res. 71:7176–7186. 2011. View Article : Google Scholar : PubMed/NCBI
20	Pannier D, Philippin-Lauridant G, Baranzelli MC, Bertin D, Bogart E, Delprat V, Villain G, Mattot V, Bonneterre J and Soncin F: High expression levels of egfl7 correlate with low endothelial cell activation in peritumoral vessels of human breast cancer. Oncol Lett. 12:1422–1428. 2016. View Article : Google Scholar : PubMed/NCBI
21	Doliana R, Bot S, Bonaldo P and Colombatti A: EMI, a novel cysteine-rich domain of EMILINs and other extracellular proteins, interacts with the gC1q domains and participates in multimerization. FEBS Lett. 484:164–168. 2000. View Article : Google Scholar : PubMed/NCBI
22	Callebaut I, Mignotte V, Souchet M and Mornon JP: EMI domains are widespread and reveal the probable orthologs of the caenorhabditis elegans CED-1 protein. Biochem Biophys Res Commun. 300:619–623. 2003. View Article : Google Scholar : PubMed/NCBI
23	Campbell ID and Bork P: Epidermal growth factor-like modules. Curr Opin Struct Biol. 3:385–392. 1993. View Article : Google Scholar
24	Schmidt MHH, Bicker F, Nikolic I, Meister J, Babuke T, Picuric S, Müller-Esterl W, Plate KH and Dikic I: Epidermal growth factor-like domain 7 (EGFL7) modulates Notch signalling and affects neural stem cell renewal. Nat Cell Biol. 11:873–880. 2009. View Article : Google Scholar : PubMed/NCBI
25	Abramoff MD, Magalhães P and Ram SJ: Image processing with imageJ. Biophot Int. 11:36–42. 2004.
26	Tomayko MM and Reynolds CP: Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol. 24:148–154. 1989. View Article : Google Scholar : PubMed/NCBI
27	Chiu JJ: Shear stress increases ICAM-1 and decreases VCAM-1 and E-selectin expressions induced by tumor necrosis factor-[alpha] in endothelial cells. Arterioscler Thromb Vasc Biol. 24:73–79. 2004. View Article : Google Scholar : PubMed/NCBI
28	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
29	Durrans A and Stuhlmann H: A role for Egfl7 during endothelial organization in the embryoid body model system. J Angiogenes Res. 2:42010. View Article : Google Scholar : PubMed/NCBI
30	Nichol D, Shawber C, Fitch MJ, Bambino K, Sharma A, Kitajewski J and Stuhlmann H: Impaired angiogenesis and altered Notch signaling in mice overexpressing endothelial Egfl7. Blood. 116:6133–6143. 2010. View Article : Google Scholar : PubMed/NCBI
31	D'Audigier C, Susen S, Blandinieres A, Mattot V, Saubamea B, Rossi E, Nevo N, Lecourt S, Guerin CL, Dizier B, et al: Egfl7 represses the vasculogenic potential of human endothelial progenitor cells. Stem Cell Rev Rep. 14:82–91. 2018. View Article : Google Scholar : PubMed/NCBI
32	Taddei ML, Giannoni E, Fiaschi T and Chiarugi P: Anoikis: An emerging hallmark in health and diseases. J Pathol. 226:380–393. 2012. View Article : Google Scholar : PubMed/NCBI
33	Philippin-Lauridant G, Baranzelli MC, Samson C, Fournier C, Pinte S, Mattot V, Bonneterre J and Soncin F: Expression of Egfl7 correlates with low-grade invasive lesions in human breast cancer. Int J Oncol. 42:1367–1375. 2013. View Article : Google Scholar : PubMed/NCBI
34	Fehon RG, Kooh PJ, Rebay I, Regan CL, Xu T, Muskavitch MA and Artavanis-Tsakonas S: Molecular interactions between the protein products of the neurogenic loci Notch and delta, two EGF-homologous genes in Drosophila. Cell. 61:523–534. 1990. View Article : Google Scholar : PubMed/NCBI
35	Rebay I, Fleming RJ, Fehon RG, Cherbas L, Cherbas P and Artavanis-Tsakonas S: Specific EGF repeats of Notch mediate interactions with delta and serrate: Implications for Notch as a multifunctional receptor. Cell. 67:687–699. 1991. View Article : Google Scholar : PubMed/NCBI
36	Downing AK, Knott V, Werner JM, Cardy CM, Campbell ID and Handford PA: Solution structure of a pair of calcium-binding epidermal growth factor-like domains: Implications for the Marfan syndrome and other genetic disorders. Cell. 85:597–605. 1996. View Article : Google Scholar : PubMed/NCBI
37	Ranganathan P, Weaver KL and Capobianco AJ: Notch signalling in solid tumours: A little bit of everything but not all the time. Nat Rev Cancer. 11:338–351. 2011. View Article : Google Scholar : PubMed/NCBI
38	Hayakawa S, Koide R, Hinou H and Nishimura SI: Synthetic human NOTCH1 EGF modules unraveled molecular mechanisms for the structural and functional roles of calcium ions and O-glycans in the ligand-binding region. Biochemistry. 55:776–787. 2016. View Article : Google Scholar : PubMed/NCBI
39	Taylor P, Takeuchi H, Sheppard D, Chillakuri C, Lea SM, Haltiwanger RS and Handford PA: Fringe-mediated extension of O-linked fucose in the ligand-binding region of Notch1 increases binding to mammalian Notch ligands. Proc Natl Acad Sci USA. 111:7290–7295. 2014. View Article : Google Scholar : PubMed/NCBI
40	Hidai C, Zupancic T, Penta K, Mikhail A, Kawana M, Quertermous EE, Aoka Y, Fukagawa M, Matsui Y, Platika D, et al: Cloning and characterization of developmental endothelial locus-1: An embryonic endothelial cell protein that binds the alphavbeta3 integrin receptor. Genes Dev. 12:21–33. 1998. View Article : Google Scholar : PubMed/NCBI
41	Zhong J, Eliceiri B, Stupack D, Penta K, Sakamoto G, Quertermous T, Coleman M, Boudreau N and Varner JA: Neovascularization of ischemic tissues by gene delivery of the extracellular matrix protein Del-1. J Clin Invest. 112:30–41. 2003. View Article : Google Scholar : PubMed/NCBI
42	Aoka Y, Johnson FL, Penta K, Hirata Ki K, Hidai C, Schatzman R, Varner JA and Quertermous T: The embryonic angiogenic factor Del1 accelerates tumor growth by enhancing vascular formation. Microvasc Res. 64:148–161. 2002. View Article : Google Scholar : PubMed/NCBI
43	Choi EY, Chavakis E, Czabanka MA, Langer HF, Fraemohs L, Economopoulou M, Kundu RK, Orlandi A, Zheng YY, Prieto DA, et al: Del-1, an endogenous leukocyte-endothelial adhesion inhibitor, limits inflammatory cell recruitment. Science. 322:1101–1104. 2008. View Article : Google Scholar : PubMed/NCBI
44	Choi EY: Inhibition of leukocyte adhesion by developmental endothelial locus-1 (del-1). Immune Netw. 9:153–157. 2009. View Article : Google Scholar : PubMed/NCBI
45	Villain G, Lelievre E, Broekelmann T, Gayet O, Havet C, Werkmeister E, Mecham R, Dusetti N, Soncin F and Mattot V: MAGP-1 and fibronectin control EGFL7 functions by driving its deposition into distinct endothelial extracellular matrix locations. FEBS J. 285:4394–4412. 2018. View Article : Google Scholar : PubMed/NCBI
46	Verginelli F, Adesso L, Limon I, Alisi A, Gueguen M, Panera N, Giorda E, Raimondi L, Ciarapica R, Campese AF, et al: Activation of an endothelial Notch1-Jagged1 circuit induces VCAM1 expression, an effect amplified by interleukin-1β. Oncotarget. 6:43216–43229. 2015. View Article : Google Scholar : PubMed/NCBI
47	Nus M, Martínez-Poveda B, MacGrogan D, Chevre R, D'Amato G, Sbroggio M, Rodríguez C, Martínez-González J, Andrés V, Hidalgo A and de la Pompa JL: Endothelial Jag1-RBPJ signalling promotes inflammatory leucocyte recruitment and atherosclerosis. Cardiovasc Res. 112:568–580. 2016. View Article : Google Scholar : PubMed/NCBI
48	Quillard T, Coupel S, Coulon F, Fitau J, Chatelais M, Cuturi MC, Chiffoleau E and Charreau B: Impaired Notch4 activity elicits endothelial cell activation and apoptosis: Implication for transplant arteriosclerosis. Arterioscler Thromb Vasc Biol. 28:2258–2265. 2008. View Article : Google Scholar : PubMed/NCBI